[A case of rheumatoid arthritis with polymyositis (author's transl)].

S. Nagaoka,H. Sakamoto,M. Narita,K. Katoh,K. Matsunaga,J. Chiba,Y. Ishigatsubo,K. Tani,S. Tani

1981-09-01

Abstract:

What problem does this paper attempt to address?

Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field

Brunangelo Falini,Sofia Sciabolacci,Lorenza Falini,Lorenzo Brunetti,Maria Paola Martelli

DOI: https://doi.org/10.1038/s41375-021-01222-4

2021-04-20

Leukemia

Abstract:Abstract Mutations of Nucleophosmin ( NPM1 ) are the most common genetic abnormalities in adult acute myeloid leukaemia (AML), accounting for about 30% of cases. NPM1 -mutated AML has been recognized as distinct entity in the 2017 World Health Organization (WHO) classification of lympho-haematopoietic neoplasms. WHO criteria allow recognition of this leukaemia entity and its distinction from AML with myelodysplasia-related changes, AML with BCR-ABL1 rearrangement and AML with RUNX1 mutations. Nevertheless, controversial issues include the percentage of blasts required for the diagnosis of NPM1 -mutated AML and whether cases of NPM1 -mutated myelodysplasia and chronic myelomonocytic leukaemia do exist. Evaluation of NPM1 and FLT3 status represents a major pillar of the European LeukemiaNet (ELN) genetic-based risk stratification model. Moreover, NPM1 mutations are particularly suitable for assessing measurable residual disease (MRD) since they are frequent, stable at relapse and do not drive clonal haematopoiesis. Ideally, combining monitoring of MRD with the ELN prognostication model can help to guide therapeutic decisions. Here, we provide examples of instructive cases of NPM1 -mutated AML, in order to provide criteria for the appropriate diagnosis and therapy of this frequent leukaemia entity.

oncology,hematology
Co-mutation Landscape and Its Prognostic Impact on Newly Diagnosed Adult Patients with NPM1 Mutated De Novo Acute Myeloid Leukemia.

Yiyi Yao,Nanfang Zhuo,Yile Zhou,Liping Mao,Min Yang,Yinjun Lou,Hongyan Tong,Jie Jin,Huafeng Wang

DOI: https://doi.org/10.1038/s41408-024-01103-w

IF: 45.3

2024-01-01

Journal of Clinical Oncology

Abstract:e18505 Background: 25-35% of adult patients with acute myeloid leukemia (AML) carries NPM1 mutation, characterized by aberrant cytoplasmic dislocation of NPM1 protein, which is generally associated with a favorable outcome in the absence of FLT3-ITD mutation. Indeed, for NPM1-mutated AML patients with different co-mutation profiles, identification of specific co-mutation combinations other than FLT3-ITD mutation is necessary for accurate risk stratification and contributes to identify the optimal population who may benefit from allogeneic hematopoietic stem cell transplantation (allo-HSCT) during post-remission therapy. Methods: Eligible patients included newly diagnosed adult patients (≥18 years old) with NPM1 mutated de novo AML (M3 excluded) treated at the First Affiliated Hospital of Zhejiang University School of Medicine for at least one complete course of induction therapy from October 2018 to December 2022. All patients received next generation sequencing (NGS) detection for diagnosis before treatment. Response was evaluated within two courses of induction chemotherapy. Overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) were collected for endpoint analysis. Results: 178 patients were analyzed. Median age was 59 years old (IQR, 51-68). The co-mutated genes with a detection rate of ≥ 10% included FLT3, DNMT3A, TET2, IDH2, IDH1, PTPN11, NRAS, and WT1. The median follow-up was 26.2 months. Our results showed that in NPM1 mutated AML, co-mutations of IDH1, IDH2, and PTPN11-PTP domain were associated with favorable prognosis, while co-mutations of FLT3-ITD and DNMT3A were associated with poor prognosis. Interestingly, the adverse outcome trends brought by FLT3-ITD and DNMT3A co-mutations could be reversed by IDH mutation and PTPN11 mutations, respectively (Table). Besides, for NPM1 mutated AML patients combined with FLT3-ITD/ DNMT3A mutations, allo-HSCT after remission could significantly improve outcome ( P < 0.05), while similar results were not found in FLT3-ITD/ DNMT3A wild type patients. Conclusions: This study demonstrated that NPM1-mutated AML with different co-mutation profiles led to heterogeneous outcomes. For NPM1-mutated AML patients with adverse prognosis-related co-mutation combinations, allo-HSCT after remission may be a recommended strategy to improve outcome. [Table: see text]
Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML

Brunangelo Falini,Richard Dillon

DOI: https://doi.org/10.1158/2643-3230.BCD-23-0144

2024-01-08

Abstract:NPM1-mutated acute myeloid leukemia (AML) represents the largest molecular subgroup of adult AML. NPM1-mutated AML is recognizable by molecular techniques and immunohistochemistry, which, when combined, can solve difficult diagnostic problems (including identification of myeloid sarcoma and NPM1 mutations outside exon 12). According to updated 2022 European LeukemiaNet (ELN) guidelines, determining the mutational status of NPM1 (and FLT3) is a mandatory step for the genetic-based risk stratification of AML. Monitoring of measurable residual disease (MRD) by qRT-PCR, combined with ELN risk stratification, can guide therapeutic decisions at the post-remission stage. Here, we review the criteria for appropriate diagnosis and molecular monitoring of NPM1-mutated AML. Significance: NPM1-mutated AML represents a distinct entity in the 2022 International Consensus Classification and 5th edition of World Health Organization classifications of myeloid neoplasms. The correct diagnosis of NPM1-mutated AML and its distinction from other AML entities is extremely important because it has clinical implications for the management of AML patients, such as genetic-based risk stratification according to 2022 ELN. Monitoring of MRD by qRT-PCR, combined with ELN risk stratification, can guide therapeutic decisions at the post-remission stage, e.g., whether or not to perform allogeneic hematopoietic stem cell transplantation.
Mutations of the Nucleophosmin (NPM1) Gene Are Common in Adult Acute Myeloid Leukemia and Associated with Favorable Prognosis If Present without FLT3-ITD Mutation.

Christian Thiede,Sina Koch,Eva Creutzig,Christine Steudel,Thomas Illmer,Markus Schaich,Gerhard Ehninger

DOI: https://doi.org/10.1182/blood.v106.11.224.224

IF: 20.3

2005-11-16

Blood

Abstract:Abstract Nucleophosmin (NPM1) is a nucleo-cytoplasmic shuttling protein with multiple functions, including regulation of the p53-ARF pathway. Rearranged NPM1 has been found in a small subgroup of AML patients with t(5;17). Recently, mutations of NPM1 have been described in patients with acute myeloid leukaemia, especially in patients with normal karyotype (Falini et al, NEJM 2005). These mutations lead to an elongated protein which is retained in the cytoplasm. The precise prevalence as well as the long term clinical impact of this mutation is currently unclear. Patients and methods: We investigated 1485 samples from adult patients with newly diagnosed AML and advanced MDS for mutations in exon 12 of the NPM1 gene. The majority of these individuals were treated in the AML96 protocol of the DSIL (former SHG). Mutations in NPM1 exon 12 were screened using genomic DNA from the time of diagnosis and Genescan analysis. In a subgroup, mutations were confirmed by sequencing. In addition, confocal laser scanning microscopy was performed to investigate the localization of mutant NPM1 in cases with novel mutations. Results: A 4-bp insert in the genomic sequence was detected in 408/1485 patients (27.5%). In 229 cases sequenced so far the most common change was the previously reported Type A (80.3%), followed by B (9.2%) and D (3.1) and 13 novel mutations, which showed cytoplasmic localization of NPM1 in all five analyzed cases. The NPM1-mutations were most prevalent in patients with normal karyotype (324/709; 45.7%) compared to 58/686 with karyotype abnormalities (8.5%) (P<.0001). NPM1 mutations were rarely seen in cases with good risk abnormalities [t(8;21): 2/57; inv(16: 2/73; t(15;17): 0/47] but also rarely detected together with high risk cytogenetics [-5/5q-: 3/94;-7/7q-: 5/122; complex: 4/185]. The mutation was found to be associated with high WBC counts, high BM blasts and higher platelet counts (P <.0001). Mutant NPM1 was also more prevalent in females compared to males (33.1 vs 22.9%; P<.00001). Most NPM1 mutations were found in cases with de novo AML, mainly in FAB subgroups M5a, M5b, and M4, and were absent or rare in M3, M0, M6, and M7. Patients with NPM1 alterations had significantly more FLT3-ITD mutations, even if restricted to patients with normal karyotype (NPM1-mut: 43.8% vs. NPM1-wt: 19.9%; p<.0001), whereas a significantly lower rate of MLL-PTD mutations was found (NPM1-mut: 0/207 vs. NPM1-wt: 39/549; P<.0001). To assess the clinical impact, 4 groups were defined based on the NPM1 and FLT3-ITD status for patients with normal karyotype: NPM1-mut/FLT3-ITD neg; NPM1-mut/FLT3-ITD pos; NPM1-wt/FLT3-ITD pos; NPM1-wt/ FLT3-ITD neg. Among these groups, patients having only an NPM1-mutation had significantly better overall survival (OS), disease free survival (DFS) and a lower probability of relapse, compared to all other groups. This was confirmed in a multivariate analysis (HR NPM1-mut/FLT3-ITD neg for OS: 0.76 95% CI: 0.587–.992; DFS: 0.661, 95% CI: 0.449–0.973). In addition, these patients had a significantly lower cumulative incidence of relapse (CIR at 40 months: 37.2%; P = .009). Conclusion: With more than 27%, NPM1-mutations represent the most frequent genetic abnormality in adult AML identified so far. They characterize a specific subset in patients with normal karyotype. If not associated with FLT3-ITD mutations, NPM1 abnormalities appear to identify a subgroup with improved response towards treatment. The mechanistic background remains to be determined.

hematology
NPM1‐mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions

Brunangelo Falini

DOI: https://doi.org/10.1002/ajh.26989

IF: 13.265

2023-06-16

American Journal of Hematology

Abstract:The nucleophosmin (NPM1) gene encodes for a multifunctional chaperone protein that is localized in the nucleolus but continuously shuttles between the nucleus and cytoplasm. NPM1 mutations occur in about one‐third of AML, are AML‐specific, usually involve exon 12 and are frequently associated with FLT3‐ITD, DNMT3A, TET2, and IDH1/2 mutations. Because of its unique molecular and clinico‐pathological features, NPM1‐mutated AML is regarded as a distinct leukemia entity in both the International Consensus Classification (ICC) and the 5th edition of the World Health Organization (WHO) classification of myeloid neoplasms. All NPM1 mutations generate leukemic mutants that are aberrantly exported in the cytoplasm of the leukemic cells and are relevant to the pathogenesis of the disease. Here, we focus on recently identified functions of the NPM1 mutant at chromatin level and its relevance in driving HOX/MEIS gene expression. We also discuss yet controversial issues of the ICC/WHO classifications, including the biological and clinical significance of therapy‐related NPM1‐mutated AML and the relevance of blasts percentage in defining NPM1‐mutated AML. Finally, we address the impact of new targeted therapies in NPM1‐mutated AML with focus on CAR T cells directed against NPM1/HLA neoepitopes, as well as XPO1 and menin inhibitors.

hematology
NPM 1 Mutations in AML—The Landscape in 2023

Naman Sharma,Jane L. Liesveld

DOI: https://doi.org/10.3390/cancers15041177

2023-02-12

Cancers

Abstract:Acute myeloid leukemia (AML) represents 80% of acute leukemia in adults and is characterized by clonal expansion of hematopoietic stem cells secondary to genomic mutations, rendering a selective growth advantage to the mutant clones. NPM1mut is found in around 30% of AML and clinically presents with leukocytosis, high blast percentage and extramedullary involvement. Considered as a "gate-keeper" mutation, NPM1mut appears to be a "first hit" in the process of leukemogenesis and development of overt leukemia. Commonly associated with other mutations (e.g., FLT 3, DNMT3A, TET2, SF3B1), NPM1 mutation in AML has an important role in diagnosis, prognosis, treatment and post-treatment monitoring. Several novel therapies targeting NPM1 are being developed in various clinical phases with demonstration of efficacy. In this review, we summarize the pathophysiology of the NPM1 gene mutation in AML, clinical implications and the novel targeted therapies to date.

oncology
Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Yang Shen,Yong-Mei Zhu,Xing Fan,Jing-Yi Shi,Qin-Rong Wang,Xiao-Jing Yan,Zhao-Hui Gu,Yan-Yan Wang,Bing Chen,Chun-Lei Jiang,Han Yan,Fei-Fei Chen,Hai-Min Chen,Zhu Chen,Jie Jin,Sai-Juan Chen

DOI: https://doi.org/10.1182/blood-2011-03-343988

IF: 20.3

2011-01-01

Blood

Abstract:To evaluate the prognostic value of genetic mutations for acute myeloid leukemia (AML) patients, we examined the gene status for both fusion products such as AML1 (CBF alpha)-ETO, CBF beta-MYH11, PML-RAR alpha, and MLL rearrangement as a result of chromosomal translocations and mutations in genes including FLT3, C-KIT, N-RAS, NPM1, CEBPA, WT1, ASXL1, DNMT3A, MLL, IDH1, IDH2, and TET2 in 1185 AML patients. Clinical analysis was mainly carried out among 605 cases without recognizable karyotype abnormalities except for 11q23. Of these 605 patients, 452 (74.7%) were found to have at least 1 mutation, and the relationship of gene mutations with clinical outcome was investigated. We revealed a correlation pattern among NPM1, DNMT3A, FLT3, IDH1, IDH2, CEBPA, and TET2 mutations. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event-free survival (EFS), whereas biallelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in both the whole group and among younger patients < 60 years of age. The use of molecular markers allowed us to subdivide the series of 605 patients into distinct prognostic groups with potential clinical relevance. (Blood. 2011;118(20):5593-5603)
FLT3 and NPM1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Normal Cytogenetics

Lei Wang,Wei-lai Xu,Hai-tao Meng,Wen-bin Qian,Wen-yuan Mai,Hong-yan Tong,Li-ping Mao,Yin Tong,Jie-jing Qian,Yin-jun Lou,Zhi-mei Chen,Yun-gui Wang,Jie Jin

DOI: https://doi.org/10.1631/jzus.b1000052

2010-01-01

Journal of Zhejiang University SCIENCE B

Abstract:Mutations of fms-like tyrosine kinase 3 (FLT3) and nucleophosmin (NPM1) exon 12 genes are the most common abnormalities in adult acute myeloid leukemia (AML) with normal cytogenetics. To assess the prognostic impact of the two gene mutations in Chinese AML patients, we used multiplex polymerase chain reaction (PCR) and capillary electrophoresis to screen 76 AML patients with normal cytogenetics for mutations in FLT3 internal tandem duplication (FLT3/ITD) and exon 12 of the NPM1 gene. FLT3/ITD mutation was detected in 15 (19.7%) of 76 subjects, and NPM1 mutation in 20 (26.3%) subjects. Seven (9.2%) cases were positive for both FLT3/ITD and NPM1 mutations. Significantly more FLT3/ITD aberration was detected in subjects with French-American-British (FAB) M1 (42.8%). NPM1 mutation was frequently detected in subjects with M5 (47.1%) and infrequently in subjects with M2 (11.1%). FLT3 and NPM1 mutations were significantly associated with a higher white blood cell count in peripheral blood and a lower CD34 antigen expression, but not age, sex, or platelet count. Statistical analysis revealed that the FLT3/ITDpositive group had a lower complete remission (CR) rate (53.3% vs. 83.6%). Survival analysis showed that the FLT3/ITD-positive/NPM1 mutation-negative group had worse overall survival (OS) and relapse-free survival (RFS). The FLT3/ITD-positive/NPM1 mutation-positive group showed a trend towards favorable survival compared with the FLT3/ITD-positive/NPM1 mutation-negative group (P=0.069). Our results indicate that the FLT3/ITD mutation might be a prognostic factor for an unfavorable outcome in Chinese AML subjects with normal cytogenetics, while NPM1 mutation may be a favorable prognostic factor for OS and RFS in the presence of FLT3/ITD.
Recent advances in AML with mutated NPM1

Yuichi Ishikawa,Yoko Ushijima,Hitoshi Kiyoi

DOI: https://doi.org/10.1007/s12185-024-03835-8

2024-08-22

Abstract:Nucleophosmin 1 (NPM1) mutation is one of the most prevalent genetic mutations in adult acute myeloid leukemia (AML) and is particularly predominant in AML with a normal karyotype. NPM1 is a chaperone protein that plays various roles in several cellular processes. Wild-type NPM1 is normally localized to the nucleus, whereas mutant NPM1 proteins exhibit altered cytoplasmic localization. Clinically, AML with mutated NPM1 without FLT3-ITD is associated with a higher complete remission rate and improved overall survival. AML with mutated NPM1 is categorized as a distinct genetic entity in the World Health Organization classification of hematopoietic malignancies due to its unique clinical and biological features. However, the precise roles of NPM1 in normal hematopoiesis and in AML development remain unclear. Recent studies have revealed various clinical applications of NPM1 mutations in AML treatment, particularly in measurable residual disease analyses that target mutant NPM1 transcripts and in potential therapeutic applications of menin inhibitors and XPO-1 inhibitors for AML with mutated NPM1. Thus, NPM1 mutation is highly significant in AML classification, prognosis, response assessment, and molecular targeted therapies. Here, we review recent progress in clinical and biological aspects of AML with mutated NPM1 including molecular targeted therapy.
Characteristics and Prognosis of "Acute Promyelocytic Leukemia-like" Nucleophosmin-1-Mutated Acute Myeloid Leukemia in a Retrospective Patient Cohort

Vasiliki Papadopoulou,Giulia Schiavini,Gregoire Stalder,Valentin Basset,Jacqueline Schoumans,Mitja Nabergoj,Muriel Schaller

DOI: https://doi.org/10.3390/biomedicines12102282

IF: 4.757

2024-10-10

Biomedicines

Abstract:Background: AML with NPM1 mutation is the largest subcategory of AML, representing about 35% of AML cases. It is characterized by CD34 negativity, which suggests a relatively differentiated state of the bulk of leukemic blasts. Notably, a significant subset of NPM1-mutated AML cases also exhibit HLA-DR negativity, classifying them as "double-negative", and mimicking, therefore, the CD34− HLA-DR− immunophenotype of acute promyelocytic leukemia (APL). Objectives: This study focuses on the "acute promyelocytic leukemia-like" ("APL-like") subset of NPM1-mutated AML, which can be challenging to distinguish from APL at presentation, prior to confirming RARa translocations. We aim to investigate the hematologic and immunophenotypic parameters that may aid to its distinction from APL. Additionally, we explore differences in genetic profile and prognosis between "APL-like" and "non-APL-like" NPM1-mutated AML cases. Methods: We conducted a retrospective evaluation of 77 NPM1-mutated AML cases and 28 APL cases. Results: Morphological characteristics, hematologic parameters (such as DD/WBC and PT/WBC), and specific immunophenotypic markers (including SSC, CD64, and CD4) can assist in the early distinction of "APL-like" NPM1-mutated AML from APL. Regarding differences in genetic profiles and outcomes between "APL-like" and non-"APL-like" NPM1-mutated AML cases, we observed a significantly higher incidence of IDH1/2 /TET2 mutations, along with a significantly lower incidence of DNMT3A mutations in the "APL-like" subset compared to the non-"APL-like" subset. The frequency of Ras-pathway and FLT3 mutations did not differ between these last two groups, nor did their prognoses. Conclusions: Our findings contribute to a comprehensive characterization of NPM1-mutated AML, enhancing diagnostic accuracy and aiding in the detailed classification of the disease. This information may potentially guide targeted therapies or differentiation-based treatment strategies.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia

Shano Naseem,Jogeshwar Binota,Neelam Varma,Harpreet Virk,Subhash Varma,Pankaj Malhotra

DOI: https://doi.org/10.18502/ijhoscr.v15i1.5246

2021-01-23

Abstract:Background: A number of mutations have been reported to occur in patients with acute myeloid leukemia (AML), of which NPM1 and FLT3 genes mutations are the commonest and have important diagnostic and therapeutic implications. Material and Methods: Molecular testing for NPM1 and FLT3 genes was performed in 92 de-novo AML patients. The frequency and characteristics of NPM1 and FLT3 mutations were analyzed. Results: Nucleophosmin 1(NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutations were seen in 22.8% and 16.3% of patients, respectively. Amongst FLT3 mutations, FLT3-ITD mutation was seen in 8.7% cases, FLT3- TKD in 5.4%, and FLT3-ITD+TKD in 2.2% cases. Certain associations between the gene mutations and clinical characteristics were found, including in NPM1 mutated group- female preponderance, higher incidence in M4/M5 categories and decreased expression of CD34 and HLA-DR; and in FLT3-ITD mutated group- higher age of presentation, higher total leucocyte count and blast percentage. Conclusion- AML patients with NPM1 and FLT3 mutations have differences in clinical and hematological features, which might represent their different molecular mechanism in leukemogenesis. The frequency of NPM1 and FLT3 mutations in this study was comparable to reports from Asian countries but lower than that reported from western countries. However, as the number of patients in the study was less, a larger number of patients need to be studied to corroborate these findings.
Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia

Jochen Greiner,Eithar Mohamed,Daniel M. Fletcher,Patrick J. Schuler,Hubert Schrezenmeier,Marlies Götz,Barbara-ann Guinn

DOI: https://doi.org/10.3390/cancers16203443

2024-10-12

Cancers

Abstract:Acute myeloid leukemia (AML) is a malignant disease of the blood and bone marrow that is characterized by uncontrolled clonal proliferation of abnormal myeloid progenitor cells. Nucleophosmin 1 (NPM1) gene mutations are the most common genetic abnormality in AML, detectable in blast cells from about one-third of adults with AML. AML NPM1mut is recognized as a separate entity in the World Health Organization classification of AML. Clinical and survival data suggest that patients with this form of AML often have a more favorable prognosis, which may be due to the immunogenicity created by the mutations in the NPM1 protein. Consequently, AML with NPM1mut can be considered an immunogenic subtype of AML. However, the underlying mechanisms of this immunogenicity and associated favorable survival outcomes need to be further investigated. Immune checkpoint molecules, such as the programmed cell death-1 (PD-1) protein and its ligand, PD-L1, play important roles in leukemogenesis through their maintenance of an immunosuppressive tumor microenvironment. Preclinical trials have shown that the use of PD-1/PD-L1 checkpoint inhibitors in solid tumors and lymphoma work best in novel therapy combinations. Patients with AML NPM1mut may be better suited to immunogenic strategies that are based on the inhibition of the PD-1 immune checkpoint pathway than patients without this mutation, suggesting the genetic landscape of patients may also inform best practice for the use of PD-1 inhibitors.

oncology
Significance of NPM1 Gene Mutations in AML

Andrew Hindley,Mark Alexander Catherwood,Mary Frances McMullin,Ken I. Mills

DOI: https://doi.org/10.3390/ijms221810040

IF: 5.6

2021-09-17

International Journal of Molecular Sciences

Abstract:The aim of this literature review is to examine the significance of the nucleophosmin 1 (NPM1) gene in acute myeloid leukaemia (AML). This will include analysis of the structure and normal cellular function of NPM1, the type of mutations commonly witnessed in NPM1, and the mechanism by which this influences the development and progression of AML. The importance of NPM1 mutation on prognosis and the treatment options available to patients will also be reviewed along with current guidelines recommending the rapid return of NPM1 mutational screening results and the importance of employing a suitable laboratory assay to achieve this. Finally, future developments in the field including research into new therapies targeting NPM1 mutated AML are considered.

biochemistry & molecular biology,chemistry, multidisciplinary
[The Clinical Characteristics of Newly Diagnosed Acute Myeloid Leukemia Patients with NPM1 Mutation].

Hong‐Hu Zhu,Bin Jiang,Xi-jing Lu,Qian Jiang,Hao Jiang,Li Bao,Xiao‐Hui Zhang,Jin Lü,Guo‐Rui Ruan,Yue‐Yun Lai,Yanrong Liu,Xiao‐Jun Huang

2010-01-01

Abstract:To investigate the clinical characteristics of newly diagnosed acute myeloid leukemia (AML) with NPM1 mutation.NPM1 mutation (including A, B, D mutation type) was detected in 206 patients with newly diagnosed AML by real-time quantitative RT-PCR.The incidence of NPM1 mutation was 15.5% in total AML patients and 32.5% in normal karyotypes AML patients. The characteristics of 174 NPM1 wild type patients v.s. that of 32 NPM1 mutation patients was as follow, median age (46 vs 35 years old, P < 0.01), WBC counts (27 × 10(9)/L vs 8 × 10(9)/L, P < 0.01), BPC (82 × 10(9)/L vs 36 × 10(9)/L, P < 0.01), proportion of AML-M(5) (31.2% vs 5.8%, P = 0.01), incidence of normal karyotypes (92.6% vs 40.8%, P < 0.01), incidence of FLT3-ITD-positive (25.0% vs 7.5%, P < 0.01), CD34-positvie (23.3% vs 69.5%, P < 0.01), cases with fusion gene (0 vs 47.1%, P < 0.01). No statistic difference was found in sex, percentage of blasts in bone marrow, complete remission rate, overall survival between the two groups. Relapse-free survival in AML patients with NPM1-mutation and FLT3-ITD-negative tended to be higher than in those with NPM1-mutation and FLT3-ITD-positive.It is necessary to detect NPM1 mutation and FLT3-ITD in newly diagnosed AML patients, especially in patients with high WBC and BPC, CD34-negative, normal karyotype, which might help to molecular classification and treatment.
Clinical Characteristics of NPM1 Gene Mutation in Acute Myelogenous Leukemia

Ji-yan ZOU,Ping ZHU,Li-peng ZHANG,Hong-xing LIU

2010-01-01

Abstract:Objective To analyze nucleophosmin ( NPM1) gene exon12 mutations in patients with acute myeloid leukemia( AML) ,we explored the clinical characters of AML patients with NPM1 mutation. Methods Genomic DNAs from 98 acute leukemia and myelodysplastic syndrome ( MDS) patients were extracted,including 78 AML,10 ALL and 10 MDS. Genomic DNAs from all patients were amplified by multi-PCR for NPM1 exon 12 and FLT3 exon14,15,then screened gene mutations of NPM1 and FLT3 by PCR-capillary electrophoresis simultaneously. Results NPM1 gene mutations were present in 26. 9% of the overall 78 AML patients. There were no NPM1 gene mutation in 10 ALL and 10 MDS patients. NPM1 gene mutations were more prevelant in patients with normal karyotype-AML ( NK-AML) ( 19 /52,36. 5% ) compared with that in those with abnormal karyotype AML( 2 /26,7. 7% ) ( P 0. 05). NPM1 mutations were more frequently seen in M2 and M5 patients. NPM1 mutation cases were significantly associated with older age 53( 18-77) vs. 43( 17-73) ,P 0. 05,and high peripheral white cell counts 42. 0( 16. 3-102. 0) × 109 /L vs. 14. 0 ( 3. 4-67. 2) × 109 /L,P 0. 05. FLT3-ITD mutation was more frequent inNPM1 mutant than wild cases ( 57. 1% vs. 22. 8% ,P 0. 05). 8/9 NPM1 + /FLT3-ITD -,3/12 NPM1 + / FLT3-ITD + ,16/33 NPM1 -/FLT3-ITD and 2/13 NPM1 -/FLT3-ITD + patients gained CR1. Compared with the other groups,NPM1 + /FLT3-ITD -patients owed higher CR1 ( P 0. 05). Conclusions NPM1 gene mutations were the prevelant mutations in patients with AML,especially in those with NK-AML. The clinical characters of AML with NPM1 mutations were significantly associated with older age,high peripheral WBC,subtype M2,M5,high incidence of FLT3-ITD mutations and high CR1.
The correlation of next-generation sequencing-based genotypic profiles with clinicopathologic characteristics in NPM1-mutated acute myeloid leukemia

Biao Wang,Bin Yang,Wei Wu,Xuan Liu,Haiqian Li

DOI: https://doi.org/10.1186/s12885-021-08455-7

IF: 4.638

2021-07-08

BMC Cancer

Abstract:Abstract The purpose of this study was to analyze the association between next-generation sequencing (NGS) genotypic profiles and conventional clinicopathologic characteristics in patients with acute myeloid leukemia (AML) with NPM1 mutation ( NPM1 mut ). We selected 238 NPM1 mut patients with available NGS information on 112 genes related to blood diseases using the χ 2 and Mann-Whitney U tests and a multivariable logistic model to analyze the correlation between genomic alterations and clinicopathologic parameters. Compared with the NPM1 mut / FLT3- ITD (−) group, the NPM1 mut / FLT3- ITD (+) group presented borderline frequent M5 morphology [78/143 (54.5%) vs. 64/95 (67.4%); P = 0.048], higher CD34- and CD7-positive rates (CD34: 20.6% vs. 47.9%, P < 0.001; CD7: 29.9% vs. 61.5%, P < 0.001) and a lack of favorable−/adverse-risk karyotypes (6.4% vs. 0%; P = 0.031). In the entire NPM1 mut cohort, 240 NPM1 mutants were identified, of which 10 (10/240, 4.2%) were missense types. When confining the analysis to the 205 cases with NPM1 mut insertions/deletions-type and normal karyotype, multivariable logistic analysis showed that FLT3- ITD was positively correlated with CD34 and CD7 expressions ( OR = 5.29 [95% CI 2.64–10.60], P < 0.001; OR = 3.47 [95% CI 1.79–6.73], P < 0.001, respectively). Ras-pathway mutations were positively correlated with HLA-DR expression ( OR = 4.05 [95% CI 1.70–9.63], P = 0.002), and KRAS mutations were negatively correlated with MPO expression ( OR = 0.18 [95% CI 0.05–0.62], P = 0.007). DNMT3A -R882 was positively correlated with CD7 and HLA-DR expressions ( OR = 3.59 [95% CI 1.80–7.16], P < 0.001; OR = 13.41 [95% CI 4.56–39.45], P < 0.001, respectively). DNMT3A mutation was negatively correlated with MPO expression ( OR = 0.35 [95% CI 1.48–8.38], P = 0.004). TET2 / IDH1 mutations were negatively correlated with CD34 and CD7 expressions ( OR = 0.26 [95% CI 0.11–0.62], P = 0.002; OR = 0.30 [95% CI 0.14–0.62], P = 0.001, respectively) and positively correlated with MPO expression ( OR = 3.52 [95% CI 1.48–8.38], P = 0.004). In conclusion, NPM1 mut coexisting mutations in signaling pathways ( FLT3- ITD and Ras-signaling pathways) and methylation modifiers ( DNMT3A and TET2 / IDH1 ) are linked with the expressions of CD34, CD7, HLA-DR and MPO, thereby providing a mechanistic explanation for the immunophenotypic heterogeneity of this AML entity.

oncology
Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach

Jessica Petiti,Ymera Pignochino,Aurora Schiavon,Emilia Giugliano,Enrico Berrino,Giorgia Giordano,Federico Itri,Matteo Dragani,Daniela Cilloni,Marco Lo Iacono

DOI: https://doi.org/10.3390/ijms25073631

IF: 5.6

2024-03-25

International Journal of Molecular Sciences

Abstract:Acute myeloid leukemia (AML) is a complex hematologic malignancy with high morbidity and mortality. Nucleophosmin 1 (NPM1) mutations occur in approximately 30% of AML cases, and NPM1-mutated AML is classified as a distinct entity. NPM1-mutated AML patients without additional genetic abnormalities have a favorable prognosis. Despite this, 30–50% of them experience relapse. This study aimed to investigate the potential of total RNAseq in improving the characterization of NPM1-mutated AML patients. We explored genetic variations independently of myeloid stratification, revealing a complex molecular scenario. We showed that total RNAseq enables the uncovering of different genetic alterations and clonal subtypes, allowing for a comprehensive evaluation of the real expression of exome transcripts in leukemic clones and the identification of aberrant fusion transcripts. This characterization may enhance understanding and guide improved treatment strategies for NPM1mut AML patients, contributing to better outcomes. Our findings underscore the complexity of NPM1-mutated AML, supporting the incorporation of advanced technologies for precise risk stratification and personalized therapeutic strategies. The study provides a foundation for future investigations into the clinical implications of identified genetic variations and highlights the importance of evolving diagnostic approaches in leukemia management.

biochemistry & molecular biology,chemistry, multidisciplinary
Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

Sandra Castaño-Díez,José Ramón Álamo,Mònica López-Guerra,Marta Gómez-Hernando,Inés Zugasti,Carlos Jiménez-Vicente,Francesca Guijarro,Irene López-Oreja,Daniel Esteban,Paola Charry,Víctor Torrecillas,Lucia Mont-de Torres,Albert Cortés-Bullich,Álex Bataller,Ares Guardia,Daniel Munárriz,Esther Carcelero,Gisela Riu,Ana Triguero,Natalia Tovar,Dolors Vela,Silvia Beà,Dolors Costa,Dolors Colomer,Maria Rozman,Jordi Esteve,Marina Díaz-Beyá

DOI: https://doi.org/10.1093/oncolo/oyae246

2024-09-30

The Oncologist

Abstract:Abstract The 2022 WHO revision and the ICC classification have recently modified the diagnostic criteria for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia. However, there is no consensus on whether CMML with NPM1 mutation (NPM1mut) should be diagnosed as AML. Nowadays, it is a subject of discussion because of its diagnostic and therapeutic implications. Therefore, we describe a case of a patient diagnosed with CMML NPM1mut and briefly review the literature to highlight the uncertainty about how to classify a CMML with NPM1 mutation. We emphasize the importance of a comprehensive molecular study, which is crucial to optimize the individualized treatment of patients, enabling them to access targeted therapies.

oncology
A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML)

Alessandra Venanzi,Roberta Rossi,Giovanni Martino,Ombretta Annibali,Giuseppe Avvisati,Maria Grazia Mameli,Paolo Sportoletti,Enrico Tiacci,Brunangelo Falini,Maria Paola Martelli

DOI: https://doi.org/10.3390/genes12091426

IF: 4.141

2021-09-16

Genes

Abstract:Nucleophosmin (NPM1) mutations occurring in acute myeloid leukemia (AML) (about 50 so far identified) cluster almost exclusively in exon 12 and lead to common changes at the NPM1 mutants C-terminus, i.e., loss of tryptophans 288 and 290 (or 290 alone) and creation of a new nuclear export signal (NES), at the bases of exportin-1(XPO1)-mediated aberrant cytoplasmic NPM1. Immunohistochemistry (IHC) detects cytoplasmic NPM1 and is predictive of the molecular alteration. Besides IHC and molecular sequencing, Western blotting (WB) with anti-NPM1 mutant specific antibodies is another approach to identify NPM1-mutated AML. Here, we show that among 382 AML cases with NPM1 exon 12 mutations, one was not recognized by WB, and describe the discovery of a novel combination of two mutations involving exon 12. This appeared as a conventional mutation A with the known TCTG nucleotides insertion/duplication accompanied by a second event (i.e., an 8-nucleotide deletion occurring 15 nucleotides downstream of the TCTG insertion), resulting in a new C-terminal protein sequence. Strikingly, the sequence included a functional NES ensuring cytoplasmic relocation of the new mutant supporting the role of cytoplasmic NPM1 as critical in AML leukemogenesis.

genetics & heredity
Targeted therapy in NPM1-mutated AML: Knowns and unknowns

Rong Wang,Pan Xu,Lin-Lin Chang,Shi-Zhong Zhang,Hong-Hu Zhu

DOI: https://doi.org/10.3389/fonc.2022.972606

IF: 4.7

2022-09-27

Frontiers in Oncology

Abstract:Acute myeloid leukemia (AML) is a heterogeneous disease characterized by malignant proliferation of myeloid hematopoietic stem/progenitor cells. NPM1 represents the most frequently mutated gene in AML and approximately 30% of AML cases carry NPM1 mutations. Mutated NPM1 result in the cytoplasmic localization of NPM1 (NPM1c). NPM1c interacts with other proteins to block myeloid differentiation, promote cell proliferation and impair DNA damage repair. NPM1 is a good prognostic marker, but some patients ultimately relapse or fail to respond to therapy. It is urgent for us to find optimal therapies for NPM1-mutated AML. Efficacy of multiple drugs is under investigation in NPM1-mutated AML, and several clinical trials have been registered. In this review, we summarize the present knowledge of therapy and focus on the possible therapeutic interventions for NPM1-mutated AML.

oncology

[A case of rheumatoid arthritis with polymyositis (author's transl)].

Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field

Co-mutation Landscape and Its Prognostic Impact on Newly Diagnosed Adult Patients with NPM1 Mutated De Novo Acute Myeloid Leukemia.

Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML

Mutations of the Nucleophosmin (NPM1) Gene Are Common in Adult Acute Myeloid Leukemia and Associated with Favorable Prognosis If Present without FLT3-ITD Mutation.

NPM1‐mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions

NPM 1 Mutations in AML—The Landscape in 2023

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

FLT3 and NPM1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Normal Cytogenetics

Recent advances in AML with mutated NPM1

Characteristics and Prognosis of "Acute Promyelocytic Leukemia-like" Nucleophosmin-1-Mutated Acute Myeloid Leukemia in a Retrospective Patient Cohort

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia

Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia

Significance of NPM1 Gene Mutations in AML

[The Clinical Characteristics of Newly Diagnosed Acute Myeloid Leukemia Patients with NPM1 Mutation].

Clinical Characteristics of NPM1 Gene Mutation in Acute Myelogenous Leukemia

The correlation of next-generation sequencing-based genotypic profiles with clinicopathologic characteristics in NPM1-mutated acute myeloid leukemia

Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach

Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns